Compare ADMA Biologics Inc (ADMA) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

CRDO trades at $265.55, up 9.77% in 24 hours, with strong bullish momentum from moving averages and recent earnings beats. The stock shows robust fundamentals with 35.37% net income margin and 34.41% ROE, though valuations are elevated at P/E 105.8 and P/S 37.44. Recent news highlights AI-driven growth in connectivity solutions, with revenue surging 157% YoY in Q4 2026.

Outlook remains positive given analyst consensus of $273.33 price target and 86.7% buy ratings, but high valuations and competitive pressures pose risks. Continued execution on AI networking demand could drive further upside, while any slowdown in growth may trigger multiple compression.